MétaCan
Menu
← Back to cohort

Global perspectives on clinical cancer research: A comparison of randomized controlled trial (RCT) design and outcomes across high income and low-middle income countries.

2020· article· en· W3029199437 on OpenAlexaff
Connor Wells, Shubham Sharma, Joey C. Del Paggio, Wilma M. Hopman, Bishal Gyawali, C.S. Pramesh, Richard Sullivan, Christopher M. Booth

Bibliographic record

VenueJournal of Clinical Oncology · 2020
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsThunder Bay Regional Health Sciences CentreQueen's University
Fundersnot available
KeywordsMedicineRandomized controlled trialClinical endpointClinical trialExact testSample size determinationRandomizationResearch designCohortLow and middle income countriesInternal medicineFamily medicineDeveloping country

Abstract

fetched live from OpenAlex

7021 Background: Cancer clinical trials have become increasingly international in scope. There are limited data regarding trial variation based on the economic status of the country in which they are conducted. Here we describe trial characteristics, design, and results of all RCTs published globally during 2014-2017. Methods: A structured literature search was designed using PUBMED to identify all RCTs evaluating anti-cancer therapies published during 2014-2017. Data captured included authorship, participants, study characteristics, design, and results. RCTs were classified based on the World Bank country-level economic classification of the first author [low-middle/upper-middle income countries (LMIC) and high-income countries (HIC)]. Among superiority RCTs that met the primary endpoint (i.e. statistically “positive”), we calculated the ESMO-MCBS to identify trials with substantial clinical benefit (MCBS scores 4/5 or A/B). Outcomes were compared with Chi Square or Fisher’s Exact tests. Results: The study cohort included 694 RCTs; 636 (92%) were led by HIC and 58 (8%) were led by LMIC. Compared to LMIC, RCTs in HICs were more likely to be funded by industry [73% vs 41%, p<0.001] and more likely to test novel systemic therapies [87% vs 78%, p=0.027]. LMIC studies were typically smaller (median N=220 vs N=474 participants, p<0.001) and more likely to meet their primary endpoints [66% vs 44%, p=0.002]. In “positive” superiority trials, the effect size was larger in LMICs compared to HICs (median HR 0.62 vs HR 0.84, p<0.001). The proportion of trials identifying treatments with substantial clinical benefit (ESMO MCBS 4/5/A/B) was 45% (LMIC) and 31% (HIC, p=0.291). Studies from LMIC were published in journals with lower impact factors (IF) (median IF 7 vs 21, p<0.001); a publication bias persisted when adjusted for whether a trial was positive or negative: median IF LMIC negative trial=5 vs HIC negative trial=18 (p<0.001); median IF LMIC positive trial=9 vs HIC positive trial= 26 (p<0.001). Conclusions: Only a small minority of oncology RCTs are led by investigators in LMIC; these trials are less likely to be funded by industry and more likely to meet their primary endpoint. “Positive” RCTs from LMIC identify therapies with a substantially larger effect size than HIC. These data identify a substantial publication bias against RCTs conducted in LMIC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.501
metaresearch head score (Gemma)0.642
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (broad)
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: Methods
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.990
Threshold uncertainty score0.615

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.5010.642
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0100.011
Bibliometrics0.0090.011
Science and technology studies0.0020.006
Scholarly communication0.0100.009
Open science0.0030.005
Research integrity0.0070.004
Insufficient payload (model declined to judge)0.0110.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.706
GPT teacher head0.638
Teacher spread0.068 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designObservational
DomainMethods
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicHealth Systems, Economic Evaluations, Quality of Life→French-language works237,207→